Overall, the LC3 family of proteins together account for 44.8% of gene amplifications in Breast cancer patient xenografts and 35.5% of amplifications in Neuroendocrine Prostate Cancer (Figure 3), suggesting an important role for this gene family in cancer. This evidence concerns the gene MAP1LC3A and breast carcinoma.